Jazz Pharmaceuticals plc SEC Filings

ETRADE FINANCIAL CORPORATION reported a Form 144 notice to sell 2,370 performance shares dated 02/26/2026 as compensation. The filing lists Patricia Carr in prior activity, showing a sale of 4,660 common shares on 12/05/2025.

Jazz Pharmaceuticals submitted a Form 144 notice regarding proposed issuance/sale of restricted common stock as compensation. The filing lists 10,116 restricted common shares tied to 02/26/2026 and labels the transaction type as compensation.

The filing also reports a prior sale: Mary Elizabeth Henderson sold 2,238 common shares on 12/09/2025 for $379,365. The document otherwise provides standard Form 144 disclosure items for an issuer-related restricted stock transaction.

Jazz Pharmaceuticals plc describes a rare-disease focused biopharma business built around neurology and oncology therapies, anchored by its oxybate sleep franchise and epilepsy and cancer drugs. The company emphasizes Xywav and Epidiolex/Epidyolex as its largest products, with Xywav generating $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million of net product sales in 2025.

Oncology growth is led by Zepzelca, with $307.3 million of 2025 net sales, and newer launches Ziihera and Modeyso, both approved under FDA’s accelerated approval pathway for difficult-to-treat cancers. Rylaze adds another $402.9 million, and legacy Xyrem has declined to $146.0 million amid generic and authorized generic competition.

The report highlights revenue diversification away from high-sodium Xyrem, extensive global commercialization, and a deep pipeline including HER2-targeted antibody zanidatamab, additional Vyxeos studies, early-stage oncology assets JZP815 and JZP898, and expanded indications for Epidiolex. Jazz also underscores investment in R&D talent, scalable operations, and an inclusion-focused culture across roughly 2,890 employees.

Jazz Pharmaceuticals reported record 2025 total revenues of $4.27 billion, up 5%, with fourth-quarter revenue of $1.20 billion, up 10% year over year. Growth was driven by neuroscience and oncology franchises.

Flagship sleep drug Xywav generated $1.66 billion in 2025 sales, up 12%, while Epidiolex/Epidyolex reached $1.06 billion, up 9%. Oncology net product sales were $1.13 billion, up 2%, including launches of Modeyso and Ziihera.

Despite strong revenue, Jazz posted a 2025 GAAP net loss of $356 million, compared with $560 million net income in 2024, primarily due to $948 million of acquired in‑process R&D and litigation settlements. Non‑GAAP adjusted net income was $522 million. The company generated $1.36 billion of operating cash flow and guided 2026 revenue to $4.25–$4.50 billion.

Jazz Pharmaceuticals plc executive Mary Elizabeth Henderson reported an equity award vesting. On January 16, 2026, she acquired 10,116 ordinary shares of Jazz Pharmaceuticals at a stated price of $0.0 per share. These shares relate to performance share awards originally granted on March 3, 2023, with the performance-based vesting conditions certified as achieved on January 16, 2026.

Following this transaction, Henderson beneficially owns 29,624 ordinary shares in total, held directly. She serves as SVP, Technical Operations at Jazz Pharmaceuticals. The Form 4 indicates this is a non-derivative acquisition tied to prior performance awards rather than an open-market purchase.

Jazz Pharmaceuticals executive Patricia Carr, who serves as SVP and Chief Accounting Officer, reported an acquisition of company stock. On January 16, 2026, she acquired 2,370 ordinary shares at a price of $0.0 per share. These shares will be delivered under performance share awards originally granted on March 3, 2023, after the company certified that the performance-based vesting requirements were satisfied on January 16, 2026. Following this award vesting, Carr now directly beneficially owns 9,382 ordinary shares of Jazz Pharmaceuticals.

Jazz Pharmaceuticals’ EVP & Chief Legal Officer Neena M. Patil reported equity compensation activity in the company’s ordinary shares. On January 16, 2026, she received 8,852 ordinary shares at $0.0 per share upon vesting of performance share awards that were originally granted on March 3, 2023, after performance goals were certified as achieved.

On the same date, 3,275 ordinary shares were disposed of at $171.16 per share, with the filing explaining these shares were withheld from the vesting and distribution of the performance awards to satisfy her tax obligations. After these transactions, she directly beneficially owned 53,339 ordinary shares of Jazz Pharmaceuticals.

Jazz Pharmaceuticals executive Samantha Pearce reported equity award activity in Jazz (JAZZ) shares. On January 16, 2026, she acquired 3,637 ordinary shares at a price of $0.0, delivered under performance share awards originally granted on March 3, 2023, after performance-based vesting requirements were certified as satisfied on that date.

Also on January 16, 2026, 1,599 ordinary shares were withheld at $171.16 per share to cover her tax obligations arising from the vesting and distribution of those performance share awards. After these transactions, she directly owned 42,993 ordinary shares of Jazz Pharmaceuticals. A footnote notes that she had previously acquired 140 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.

Jazz Pharmaceuticals executive Robert Iannone reported equity compensation activity involving the company’s ordinary shares. On January 16, 2026, he received 11,699 ordinary shares at a price of $0.00 per share, delivered upon the vesting of performance share awards that were granted on March 3, 2023 after performance was certified. On the same date, 4,140 ordinary shares were withheld at $171.16 per share to cover his tax obligations related to the vesting and distribution of those awards.

Following these transactions, Iannone directly beneficially owned 80,258 ordinary shares of Jazz Pharmaceuticals. The filing also notes that he previously acquired 71 ordinary shares under a Section 423 employee stock purchase plan on November 28, 2025.